Abstract
A Review on the 2016 US FDA Botanical Drug Development Guideline Based on Approvals of Veregen and Fulyzaq
Full Text
Sign-in/Register to access full text options
Published version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have